Literature DB >> 31628721

Development of a Set of Lupus-Specific, Ambulatory Care-Sensitive, Potentially Preventable Adverse Conditions: A Delphi Consensus Study.

Candace H Feldman1, Cameron Speyer1, Rachel Ashby2, Bonnie L Bermas3, Shamik Bhattacharyya2, Eliza Chakravarty4, Brendan Everett1, Elizabeth Ferucci5, Aimee O Hersh6, Francisco M Marty1, Joseph F Merola1, Rosalind Ramsey-Goldman7, Brad H Rovin8, Mary Beth Son9, Laura Tarter1, Sushrut Waikar1, Jinoos Yazdany10, Joel S Weissman2, Karen H Costenbader1.   

Abstract

OBJECTIVE: Individuals with systemic lupus erythematosus (SLE) are at high risk for infections and SLE- and medication-related complications. The present study was undertaken to define a set of SLE-specific adverse outcomes that could be prevented, or their complications minimized, if timely, effective ambulatory care had been received.
METHODS: We used a modified Delphi process beginning with a literature review and key informant interviews to select initial SLE-specific potentially preventable conditions. We assembled a panel of 16 nationally recognized US-based experts from 8 subspecialties. Guided by the RAND-UCLA Appropriateness Method, we held 2 survey rounds with controlled feedback and an interactive webinar to reach consensus regarding preventability and importance on a population level for a set of SLE-specific adverse conditions. In a final round, the panelists endorsed the potentially preventable conditions.
RESULTS: Thirty-five potential conditions were initially proposed; 62 conditions were ultimately considered during the Delphi process. The response rate was 100% for both survey rounds, 88% for the webinar, and 94% for final approval. The 25 SLE-specific conditions meeting consensus as potentially preventable and important on a population level fell into 4 categories: vaccine-preventable illnesses (6 conditions), medication-related complications (8 conditions), reproductive health-related complications (6 conditions), and SLE-related complications (5 conditions).
CONCLUSION: We reached consensus on a diverse set of adverse outcomes relevant to SLE patients that may be preventable if patients receive high-quality ambulatory care. This set of outcomes may be studied at the health system level to determine how to best allocate resources and improve quality to reduce avoidable outcomes and disparities among those at highest risk.
© 2019, American College of Rheumatology.

Entities:  

Mesh:

Year:  2021        PMID: 31628721      PMCID: PMC7165052          DOI: 10.1002/acr.24095

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  39 in total

1.  Baseline Retinal Examinations in Patients With Systemic Lupus Erythematosus Newly Initiating Hydroxychloroquine Treatment in a US Medicaid Systemic Lupus Erythematosus Population, 2000-2010.

Authors:  Tzu-Chieh Lin; Michael F Marmor; Medha Barbhaiya; Hongshu Guan; Sarah K Chen; Candace H Feldman; Karen H Costenbader
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-11       Impact factor: 4.794

2.  Low-dose aspirin for prevention of morbidity and mortality from preeclampsia.

Authors:  Jillian T Henderson; Elizabeth O'Connor; Evelyn P Whitlock
Journal:  Ann Intern Med       Date:  2014-10-21       Impact factor: 25.391

3.  Total costs and predictors of costs in patients with systemic lupus erythematosus.

Authors:  N Sutcliffe; A E Clarke; R Taylor; C Frost; D A Isenberg
Journal:  Rheumatology (Oxford)       Date:  2001-01       Impact factor: 7.580

4.  Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus.

Authors:  Emily C Somers; Wendy Marder; Gregory M Christman; Vladimir Ognenovski; W Joseph McCune
Journal:  Arthritis Rheum       Date:  2005-09

5.  Thirty-day hospital readmissions in systemic lupus erythematosus: predictors and hospital- and state-level variation.

Authors:  Jinoos Yazdany; Ben J Marafino; Mitzi L Dean; Naomi S Bardach; Reena Duseja; Michael M Ward; R Adams Dudley
Journal:  Arthritis Rheumatol       Date:  2014-10       Impact factor: 10.995

6.  Frequency of adverse drug reactions in patients with systemic lupus erythematosus.

Authors:  Janet Pope; Dana Jerome; Deborah Fenlon; Adriana Krizova; Janine Ouimet
Journal:  J Rheumatol       Date:  2003-03       Impact factor: 4.666

7.  Association of socioeconomic and demographic factors with utilization of rheumatology subspecialty care in systemic lupus erythematosus.

Authors:  Jinoos Yazdany; JoAnn Zell Gillis; Laura Trupin; Patricia Katz; Pantelis Panopalis; Lindsey A Criswell; Edward Yelin
Journal:  Arthritis Rheum       Date:  2007-05-15

8.  Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs.

Authors:  Gabriela Schmajuk; Kashif Jafri; Michael Evans; Stephen Shiboski; Milena Gianfrancesco; Zara Izadi; Sarah L Patterson; Ishita Aggarwal; Urmimala Sarkar; R Adams Dudley; Jinoos Yazdany
Journal:  Semin Arthritis Rheum       Date:  2018-11-03       Impact factor: 5.532

9.  Hospital utilization for ambulatory care sensitive conditions: health outcome disparities associated with race and ethnicity.

Authors:  James N Laditka; Sarah B Laditka; Melanie P Mastanduno
Journal:  Soc Sci Med       Date:  2003-10       Impact factor: 4.634

10.  A quality indicator set for systemic lupus erythematosus.

Authors:  Jinoos Yazdany; Pantelis Panopalis; Joann Zell Gillis; Gabriela Schmajuk; Catherine H MacLean; David Wofsy; Edward Yelin
Journal:  Arthritis Rheum       Date:  2009-03-15
View more
  7 in total

1.  Avoidable Acute Care Use for Vaccine-Preventable Illnesses Among Medicaid Beneficiaries With Lupus.

Authors:  Candace H Feldman; Chang Xu; Karen H Costenbader
Journal:  Arthritis Care Res (Hoboken)       Date:  2021-08-04       Impact factor: 5.178

2.  Utilization of preventive services in a systemic lupus erythematosus population-based cohort: a Lupus Midwest Network (LUMEN) study.

Authors:  Baptiste Chevet; Gabriel Figueroa-Parra; Jeffrey X Yang; Mehmet Hocaoglu; Shirley-Ann Osei-Onomah; Cassondra A Hulshizer; Tina M Gunderson; Divi Cornec; Kamil E Barbour; Kurt J Greenlund; Cynthia S Crowson; Alí Duarte-García
Journal:  Arthritis Res Ther       Date:  2022-09-01       Impact factor: 5.606

Review 3.  Global epidemiology of systemic lupus erythematosus.

Authors:  Megan R W Barber; Cristina Drenkard; Titilola Falasinnu; Alberta Hoi; Anselm Mak; Nien Yee Kow; Elisabet Svenungsson; Jonna Peterson; Ann E Clarke; Rosalind Ramsey-Goldman
Journal:  Nat Rev Rheumatol       Date:  2021-08-03       Impact factor: 32.286

4.  Quality of Care for Patients With Systemic Lupus Erythematosus: Data From the American College of Rheumatology RISE Registry.

Authors:  Gabriela Schmajuk; Jing Li; Michael Evans; Christine Anastasiou; Julia L Kay; Jinoos Yazdany
Journal:  Arthritis Care Res (Hoboken)       Date:  2021-12-27       Impact factor: 5.178

5.  Racial Differences in Contraception Encounters and Dispensing Among Female Medicaid Beneficiaries With Systemic Lupus Erythematosus.

Authors:  Jessica N Williams; Chang Xu; Karen H Costenbader; Bonnie L Bermas; Lydia E Pace; Candace H Feldman
Journal:  Arthritis Care Res (Hoboken)       Date:  2021-09-02       Impact factor: 5.178

6.  Bacterial infections in a pediatric cohort of primary and acquired complement deficiencies.

Authors:  Taha Al-Shaikhly; Kristen Hayward; Matthew L Basiaga; Eric J Allenspach
Journal:  Pediatr Rheumatol Online J       Date:  2020-09-24       Impact factor: 3.054

7.  The Impact of an Integrated Care Management Program on Acute Care Use and Outpatient Appointment Attendance Among High-Risk Patients With Lupus.

Authors:  Jessica N Williams; Kreager Taber; Weixing Huang; Jamie Collins; Rebecca Cunningham; Katherine McLaughlin; Christine Vogeli; Lisa Wichmann; Candace H Feldman
Journal:  ACR Open Rheumatol       Date:  2022-01-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.